Novartis collaborates with Dren Bio to discover and advance novel antibody-based immune cell engagers

Fiona Hamilton Marshall, President of the Novartis Institute for BioMedical Research, shared on LinkedIn:

“I’m pleased to share that Novartis has entered into a collaboration agreement with Dren Bio to discover and advance novel antibody-based immune cell engagers for certain cancers.

We look forward to working with the Dren Bio team on this effort, which builds on our expertise in immuno-oncology and biologics and complements the wide range of modalities and approaches.

Novartis researchers are leveraging to bring forward new therapeutic options for patients living with cancer.”

Additional information.
Source: Fiona Hamilton Marshall/LinkedIn